Physician profile
Audrey Sofair
NPI 1326139833
$1,222.64
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $208 · 2021: $319 · 2022: $530 · 2023: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $337.09 | 2021-2023 | Valtoco |
| Jazz Pharmaceuticals INC. | $258.42 | 2020-2022 | |
| Greenwich Biosciences, INC. | $145.08 | 2020-2021 | |
| Ptc Therapeutics, INC. | $109.81 | 2021-2023 | |
| Ucb, INC. | $87.53 | 2020-2023 | Briviact |
| Sunovion Pharmaceuticals INC. | $61.24 | 2020 | |
| Abbvie INC. | $59.00 | 2022-2023 | Botox |
| Aquestive Therapeutics, INC. | $57.37 | 2020-2021 | |
| Corium, LLC | $26.34 | 2023 | Azstarys |
| Biocodex, INC. | $17.53 | 2023 | Diacomit |
| Zogenix INC. | $16.23 | 2021 | |
| Eisai INC. | $16.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.88 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Sofair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.